Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.
PIPELINE REVIEWS and ANALYSIS
The World Parkinson Coalition® is a unique organization filling a niche in the global Parkinson's community by bringing the full spectrum of community members together both in person at triennial World Parkinson Congresses and virtually through many online educational programs. Learn more at www.worldpdcoalition.org
By highlighting promising areas of research in the pipeline, the PDTrialTracker tool can help foster further collaboration between patients and researchers to accelerate the path to better treatments and a cure. Insights gained through analysis of the pipeline can help set research priorities, address roadblocks, enable greater patient involvement in trial design, and increase awareness of recruitment and funding needs.
Review article, Journal of Parkinson's Disease, May 2022.
Authors: McFarthing, Kevin | Rafaloff, Gary | Baptista, Marco | Mursaleen, Leah | Fuest, Rosie | Wyse, Richard K. | Stott, Simon R.W.
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Review article, Journal of Parkinson's Disease, August 2021.
Authors: McFarthing, Kevin | Rafaloff, Gary | Baptista, Marco A.S. | Wyse, Richard K. | Stott, Simon R.W.
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Review article, Journal of Parkinson's Disease, July 2020.
Authors: McFarthing, Kevin | Buff, Susan | Rafaloff, Gary | Dominey, Thea | Wyse, Richard K. | Stott, Simon R.W.
Suggestions for improving access to PD trial data to facilitate trial awareness, recruitment, and research efforts:
This spreadsheet has 4 tabs/worksheets labeled: Phase 1 Trials, Phase 2 Trials, Phase 3 Trials, and Disease-Modifying Trials. The goal of the charts is to highlight key parameters and timelines for studies in the PD clinical trial pipeline to facilitate patient/researcher collaboration. Comments and feedback can be emailed to email@example.com.
compiled by PD research advocates Sue Buff and Gary Rafaloff
This document provides an overview of disease-modifying therapies (therapies to slow, halt or reverse progression) currently in PD clinical trials (Phase 1, 2, 3), as well as a partial listing of upcoming clinical trials. It includes links for access to more extensive information about the studies.